Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

184
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
184
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

204
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
204
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

159
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
159
Drug Regulation01:25

Drug Regulation

2.6K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.6K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

146
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
146
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk factors and early onset predictors of contralateral hip fractures following initial treatment of the other hip fracture.

BMC musculoskeletal disorders·2026
Same author

Pimobendan in Heart Failure With Preserved Ejection Fraction and Right Ventricular-Pulmonary Arterial Uncoupling　- A Randomized Clinical Trial.

Circulation journal : official journal of the Japanese Circulation Society·2026
Same author

Unapproved regenerative medicine for spinal cord injury in Japan.

Regenerative therapy·2026
Same author

Drug-coated versus conventional balloons for side branch treatment in coronary bifurcation lesions: an optical coherence tomography substudy of the OCVC-BIF randomised trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Triglyceride-Glucose Index and Clinical Outcome in Patients With Heart Failure With Preserved Ejection Fraction.

JACC. Asia·2026
Same author

The association of longitudinal NT-proBNP levels with echocardiographic measurements in heart failure with preserved ejection fraction: Insights from the PURSUIT-HFpEF registry.

International journal of cardiology·2026

Related Experiment Video

Updated: Dec 29, 2025

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Published on: June 11, 2017

11.6K

Pediatric drug development in Japan: Current issues and perspectives.

Hiroyuki Saitou1,2, Daisaku Nakatani2, Akira Myoui2

  • 1Department of Pediatrics, Osaka University Medical Hospital, Osaka, Japan.

Clinical Pediatric Endocrinology : Case Reports and Clinical Investigations : Official Journal of the Japanese Society for Pediatric Endocrinology
|February 8, 2020
PubMed
Summary

Pediatric clinical trials for drug approval in Japan lag behind adult trials due to age range, formulation, consent, and profit issues. Regulatory differences with Europe and the US further complicate pediatric drug development.

Keywords:
childrendrug developmentinvestigator-initiated clinical trialsregulationssponsor-initiated clinical trials

More Related Videos

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.0K

Related Experiment Videos

Last Updated: Dec 29, 2025

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Published on: June 11, 2017

11.6K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

13.0K

Area of Science:

  • Pediatric pharmacology and regulatory science.
  • Drug development and clinical trial management.
  • Comparative international regulatory affairs.

Background:

  • Adult clinical trials for regulatory approval are increasing in Japan.
  • Pediatric clinical trials have not seen similar growth, indicating a significant gap.
  • Several factors contribute to this discrepancy, including pediatric age range, drug formulations, consent challenges, and profitability concerns.

Purpose of the Study:

  • To analyze the current status of pediatric drug development and clinical trials in Japan.
  • To identify and discuss the challenges hindering pediatric drug development in Japan.
  • To compare Japanese regulatory processes with those in Europe and the United States (US).

Main Methods:

  • Review of existing literature and regulatory guidelines concerning pediatric drug development.
  • Comparative analysis of clinical trial requirements in Japan, Europe, and the US.
  • Discussion of proposed reasons for the low number of pediatric clinical trials in Japan.

Main Results:

  • A notable increase in adult clinical trials for regulatory approval in Japan, contrasted with stagnation in pediatric trials.
  • Identified challenges in pediatric drug development include the broad pediatric age spectrum, diverse formulation needs, difficulties in obtaining informed consent, and lower profit potential for companies.
  • Significant differences exist in regulatory requirements for pediatric drug approval between Japan, Europe, and the US.

Conclusions:

  • Japan's regulatory framework for new drugs and devices does not mandate pediatric clinical trials as stringently as Europe and the US.
  • While Europe and the US incentivize pediatric data submission (e.g., patent extensions), Japan lacks similar explicit drivers.
  • Addressing the identified challenges and aligning regulatory approaches could foster pediatric drug development in Japan.